Improved memory for reward cues following acute buprenorphine administration in humans

Psychoneuroendocrinology

Volumn 53, Issue , 2015, Pages 10-15

  Syal, Supriya ^a,b   Ipser, Jonathan ^a   Terburg, David ^a,c   Solms, Mark ^a   Panksepp, Jaak ^d   Malcolm Smith, Susan ^a   Bos, Peter A ^a,c   Montoya, Estrella R ^a,c   Stein, Dan J ^a   van Honk, Jack ^a,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF TORONTO   (Canada)

^c UTRECHT UNIVERSITY   (Netherlands)

^d WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Happy facial expression; Opioids; Reward; Short term memory

Indexed keywords

BUPRENORPHINE; PLACEBO; NARCOTIC ANALGESIC AGENT;

ACUTE DRUG ADMINISTRATION; ADULT; ANGER; ARTICLE; ASSOCIATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTIONALITY; FACIAL EXPRESSION; FEAR; FEMALE; HAPPINESS; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REWARD; SADNESS; SHORT TERM MEMORY; SINGLE DRUG DOSE; TASK PERFORMANCE; ADOLESCENT; DRUG EFFECTS; RANDOMIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; ANGER; BUPRENORPHINE; CUES; FACIAL EXPRESSION; FEAR; FEMALE; HAPPINESS; HUMANS; MALE; MEMORY, SHORT-TERM; RANDOM ALLOCATION; REWARD; YOUNG ADULT;

EID: 84922794948     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.11.009     Document Type: Article

References (36)

1. Aharon I., Etcoff N., Ariely D., Chabris C.F., O'Connor E., Breiter H.C. Beautiful faces have variable reward value: fMRI and behavioral evidence. Neuron 2001, 32(3):537-551.
2. Barbano M.F., Cador M. Opioids for hedonic experience and dopamine to get ready for it. Psychopharmacology 2006, 191(3):497-506. 10.1007/s00213-006-0521-1.
3. Berridge K.C. Pleasures of the brain. Brain Cogn. 2003, 52:106-128.
4. Bodkin J.L., Zornberg G.L., Lucas S.E., Cole J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 1995, 16:49-57.
5. Bos P.A., Panksepp J., Bluthé R.M., van Honk J. Acute effects of steroid hormones and neuropeptides on human social-emotional behavior: a review of single administration studies. Front. Neuroendocrinol. 2012, 33(1):17-35. 10.1016/j.yfrne.2011.01.002.
6. Dillon D.G., Dobbins I.G., Pizzagalli D.A. Weak reward source memory in depression reflects blunted activation of VTA/SN and parahippocampus. Soc. Cogn. Affect. Neurosci. 2013, 10.1093/scan/nst155.
7. Freitas-Ferrari M.C., Hallak J.E., Trzesniak C., Filho A.S., Machado-de-Sousa J.P., Chagas M.H., Crippa J.A. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(4):565-580. 10.1016/j.pnpbp.2010.02.028 S0278-5846(10)00075-8 [pii].
8. Fujita M., Hines C.S., Zoghbi S.S., Mallinger A.G., Dickstein L.P., Liow J.S., Zarate C.A. Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 2012, 72(7):548-554. 10.1016/j.biopsych.2012.04.030 S0006-3223(12)00414-3 [pii].
9. Hsu D.T., Sanford B.J., Meyers K.K., Love T.M., Hazlett K.E., Wang H., Zubieta J.K. Response of the mu-opioid system to social rejection and acceptance. Mol. Psychiatry 2013, 18(11):1211-1217. 10.1038/mp.2013.96.
10. Ipser J.C., Terburg D., Syal S., Phillips N., Solms M., Panksepp J., van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 2013, 38(1):166-170. 10.1016/j.psyneuen.2012.05.002.
11. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 2000, 20(3-4):349-374. S0891-0618(00)00097-1 [pii].
12. Rabiner E.A., Beaver J., Makwana A., Searle G., Long C., Nathan P.J., Bullmore E.T. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol. Psychiatry 2011, 16(8):826-835. (785). 10.1038/mp.2011.29.
13. Seah S., Asad A.B., Baumgartner R., Feng D., Williams D.S., Manigbas E., Chin C.L. Investigation of cross-species translatability of pharmacological MRI in awake nonhuman primate-A buprenorphine challenge study. PloS one 2014, 9(10):e110432. 10.1371/journal.pone.0110432.
14. van Honk J., Kessels R.P., Putman P., Jager G., Koppeschaar H.P., Postma A. Attentionally modulated effects of cortisol and mood on memory for emotional faces in healthy young males. Psychoneuroendocrinology 2003, 28(7):941-948. S0306453002001166 [pii].
15. Emrich H.M., Vogt P., Herz A. Possible antidepressive effects of opioids: action of buprenorphine. Ann. N. Y. Acad. Sci. 1982, 398(1):108-112. (Opioids in Me). 10.1111/j.1749-6632.1982.tb39483.x.
16. Freitas-Ferrari M.C., Hallak J.E., Trzesniak C., Filho A.S., Machado-de-Sousa J.P., Chagas M.H., Nardi A.E., Crippa J.A. Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(4):565-580.
17. Fujita M., Hines C.S., Zoghbi S.S., Mallinger A.G., Dickstein L.P., Liow J.S., Zhang Y., Pike V.W., Drevets W.C., Innis R.B., Zarate C.A. Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 2012, 72(7):548-554.
18. Gospic K., Gunnarsson T., Fransson P., Ingvar M., Lindefors N., Petrovic P. Emotional perception modulated by an opioid and a cholecystokinin agonist. Psychopharmacology 2007, 197(2):295-307. 10.1007/s00213-007-1032-4.
19. Ipser J.C., Terburg D., Syal S., Phillips N., Solms M., Panksepp J., Malcolm-Smith S., Thomas K., Stein D.J., van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 2013, 38(1):166-170.
20. Knutson B., Adams C.M., Fong G.W., Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 2001, 21(16):RC159.
21. Kosten T.R., Morgan C., Kosten T.A. Depressive symptoms during buprenorphine treatment of opioid abusers. J. Subst. Abuse. Treat. 1990, 7:51-54.
22. Menon V., Levitin D.J. The rewards of music listening: response and physiological connectivity of the mesolimbic system. NeuroImage 2005, 28(1):175-184. 10.1016/j.neuroimage.2005.05.053.
23. Monk C.S., Klein R.G., Telzer E.H., Schroth E.A., Mannuzza S., Moulton J.L., et al. Amygdala and nucleus accumbens activation to emotional facial expressions in children and adolescents at risk for major depression. Am. J. Psychiatry 2008, 165(1):90-98. 10.1176/appi.ajp.2007.06111917.
24. Nizhnikov M.E., Varlinskaya E.I., Petrov E.S., Spear N.E. Reinforcing properties of ethanol in neonatal rats: involvement of the opioid system. Behav. Neurosci. 2006, 120(2):267. 10.1037/0735-7044.120.2.267.
25. Panksepp J., Watt D. Why does depression hurt? Ancestral primary-process separation-distress (PANIC/GRIEF) and diminished brain reward (SEEKING) processes in the genesis of depressive affect. Psychiatry: Interpers. Biol. Process. 2011, 74(1):5-13.
26. Peciña S. Opioid reward 'liking' and 'wanting' in the nucleus accumbens. Physiol. Behav. 2008, 94(5):675-680. 10.1016/j.physbeh.2008.04.006.
27. Peciña S., Smith K.S. Hedonic and motivational roles of opioids in food reward: implications for overeating disorders. Pharmacol. Biochem. Behav. 2010, 97(1):34-46. 10.1016/j.pbb.2010.05.016.
28. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography, Comparison with monkey and rat brain. J. Chem. Neuroanat. 2000, 20(3-4):349-374.
29. Pizzagalli D.A., Holmes A.J., Dillon D.G., Goetz E.L., Birk J.L., Bogdan R., et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am. J. Psychiatry 2009, 166(6):702-710. 10.1176/appi.ajp.2008.08081201.
30. Smith K.S., Berridge K.C., Aldridge J.W. Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc. Natl. Acad. Sci. 2011, 108(27):E255-E264. 10.1073/pnas.1101920108.
31. Spanagel R., Herz A., Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 1990, 55(5):1734-1740. 10.1111/j.1471-4159.1990.tb04963.
32. Vadivelu N., Hines R.L. Buprenorphine: a unique opioid with broad clinical applications. J. Opioid Manag. 2007, 3(1):49-58.
33. Van Honk J., Kessels R.P.C., Putman P., Jager G., Koppeschaar H.P.F., Postma A. Attentionally modulated effects of cortisol and mood on memory for emotional faces in healthy young males. Psychoneuroendocrinology 2003, 28(7):941-948.
34. Van Honk J., Schutter D.J.L.G., Hermans E.J., Putman P. Low cortisol levels and the balance between punishment sensitivity and reward dependency. Neuroreport 2003, 14(15):1993-1996. 10.1097/01.wnr.0000091690.72892.ec.
35. van Honk J., Schutter D.J. Testosterone reduces conscious detection of signals serving social correction: implications for antisocial behavior. Psychol. Sci. 2007, 18:663-667.
36. Yeomans M.R., Gray R.W. Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect. Physiol. Behav. 1997, 62(1):15-21.